公开(公告)号：US20110319423A1

公开(公告)日：2011-12-29

申请号：US13123368

申请日：2009-09-28

Applicant: Jin Li ,  Rifang Yang ,  Rui Song ,  Hui Zhu ,  Ning Wu ,  Liuhong Yun ,  Ruibin Su ,  Rusheng Zhao

Inventor： Jin Li ,  Rifang Yang ,  Rui Song ,  Hui Zhu ,  Ning Wu ,  Liuhong Yun ,  Ruibin Su ,  Rusheng Zhao

IPC: A61K31/496 ,  A61P25/18 ,  A61P13/12 ,  A61P25/36 ,  A61P25/22 ,  A61P15/10 ,  C07D417/12 ,  A61P25/16

CPC classification number: A61K31/496 ,  C07D263/58 ,  C07D277/68 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.

Abstract translation: 本发明涉及由式I表示的具有调节多巴胺D3受体活性的新型哌嗪衍生物，其立体异构体，药学上可接受的盐或溶剂合物，以及包含该化合物的药物组合物，其制备方法及其用途 预防或治疗与中枢神经系统功能障碍相关的疾病，例如帕金森病，精神分裂症，药物成瘾和复发，以及肾脏保护和免疫调节，或用作研究D3R功能或与D3R功能障碍相关的疾病的工具。

公开(公告)号：US08829001B2

公开(公告)日：2014-09-09

申请号：US13123368

申请日：2009-09-28

Applicant: Jin Li ,  Rifang Yang ,  Rui Song ,  Hui Zhu ,  Ning Wu ,  Liuhong Yun ,  Ruibin Su ,  Rusheng Zhao

Inventor： Jin Li ,  Rifang Yang ,  Rui Song ,  Hui Zhu ,  Ning Wu ,  Liuhong Yun ,  Ruibin Su ,  Rusheng Zhao

IPC: A61K31/496 ,  A61K31/506 ,  C07D263/58 ,  C07D277/68 ,  C07D417/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

CPC classification number: A61K31/496 ,  C07D263/58 ,  C07D277/68 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.

Abstract translation: 本发明涉及由式I表示的具有调节多巴胺D3受体活性的新型哌嗪衍生物，其立体异构体，药学上可接受的盐或溶剂合物，以及包含该化合物的药物组合物，其制备方法及其用途 预防或治疗与中枢神经系统功能障碍相关的疾病，例如帕金森病，精神分裂症，药物成瘾和复发，以及肾脏保护和免疫调节，或用作研究D3R功能或与D3R功能障碍相关的疾病的工具。